Evidence map›Paper›PMID 27703076›Full record

ArticlemBio2016

Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.

Caitlin E Mullarkey, Mark J Bailey, Diana A Golubeva, Gene S Tan, Raffael Nachbagauer, Wenqian He, Kyle E Novakowski, Dawn M Bowdish, Matthew S Miller, Peter Palese

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
17.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Immunomodulatory Effects of PulmonaromPharmaceuticals (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Caitlin E MullarkeyDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Mark J BaileyDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Diana A GolubevaDepartment of Pathology and Molecular Medicine, Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
Gene S TanDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Raffael NachbagauerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Wenqian HeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kyle E NovakowskiDepartment of Pathology and Molecular Medicine, Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
Dawn M BowdishDepartment of Pathology and Molecular Medicine, Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
Matthew S MillerDepartment of Biochemistry and Biomedical Sciences, Institute for Infectious Disease Research, McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
Peter PaleseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA peter.palese@mssm.edu.
Icahn School of Medicine at Mount Sinai · USMcMaster University Medical Centre · CA

Funding

Toward a Universal Influenza Virus VaccineP01AI097092 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2012 to 2022
$17.6M
Understanding Human B Cell Responses to Influenza to Improve the Influenza U19AI109946 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI RAVETCH, JEFFREY VICTOR · 2014 to 2018
$9.6M
CIHRNIAID NIH HHS HHSN272201400008CNIAID NIH HHS P01 AI097092NIAID NIH HHS U19 AI109946
6 · The paper itself

Abstract

Broadly neutralizing antibodies that recognize the conserved hemagglutinin (HA) stalk have emerged as exciting new biotherapeutic tools to combat seasonal and pandemic influenza viruses. Our general understanding of the mechanisms by which stalk-specific antibodies achieve protection is rapidly evolving. It has recently been demonstrated that broadly neutralizing HA stalk-specific IgG antibodies require Fc-Fcγ receptor (FcγR) interactions for optimal protection in vivo Here we examine the neutrophil effector functions induced by stalk-specific antibodies. As the most abundant subset of blood leukocytes, neutrophils represent a critical innate effector cell population and serve an instrumental role in orchestrating downstream adaptive responses to influenza virus infection. Yet, the interplay of HA stalk-specific IgG, Fc-FcγR engagement, and neutrophils has remained largely uncharacterized. Using an in vitro assay to detect the production of reactive oxygen species (ROS), we show that human and mouse monoclonal HA stalk-specific IgG antibodies are able to induce the production of ROS by neutrophils, while HA head-specific antibodies do not. Furthermore, our results indicate that the production of ROS is dependent on Fc receptor (FcR) engagement and phagocytosis. We went on to assess the ability of monoclonal HA stalk-specific IgA antibodies to induce ROS. Consistent with our findings for monoclonal IgGs, only HA stalk-specific IgA antibodies elicited ROS production by neutrophils. This induction is dependent on the engagement of FcαR1. Taken together, our findings describe a novel FcR-dependent effector function induced by HA stalk-specific IgG and IgA antibodies, and importantly, our studies shed light on the mechanisms by which HA stalk-specific antibodies achieve protection. IMPORTANCE: The present study provides evidence that broadly neutralizing HA stalk-specific antibodies induce downstream Fc-mediated neutrophil effector functions. In addition to their ability to neutralize, this class of antibodies has been shown to rely on Fc-Fc receptor interactions for optimal protection in vivo Curiously, neutralizing antibodies that bind the HA head domain do not require such interactions. Our findings build on these previous observations and provide a more complete picture of the relationship between stalk-specific antibodies and cells of the innate immune compartment. Furthermore, our data suggest that the ability of HA stalk-specific antibodies to mediate Fc-Fc receptor engagement is epitope dependent. Overall, this work will inform the rational design of improved influenza virus vaccines and therapeutics.

Indexed as

PhagocytosisAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigen-Antibody ComplexCells, CulturedHemagglutinin Glycoproteins, Influenza VirusHumansImmunoglobulin AImmunoglobulin GMiceNeutrophilsOrthomyxoviridaeReactive Oxygen SpeciesReceptors, FcAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigen-Antibody ComplexHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin AImmunoglobulin GReactive Oxygen SpeciesReceptors, Fc

Identifiers

PMID27703076
PMCPMC5050345
OpenAlexW2529004119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.